Literature DB >> 3516615

Norfloxacin: a quinoline antibiotic.

D A Marble, J A Bosso.   

Abstract

Norfloxacin is a quinoline (quinolinecarboxylic acid) that should prove successful in treating infections that currently require hospitalization and intravenous antibiotics. Although a nalidixic acid derivative, it possesses greater antibacterial activity against gram-positive and gram-negative bacteria. Compared with other antimicrobial agents, norfloxacin is more potent than the aminoglycosides, first-, second-, and third-generation cephalosporins, tetracycline, trimethoprim-sulfamethoxazole, carbenicillin, piperacillin, nalidixic acid, oxolinic acid, cinoxacin, and enoxacin. In the clinical studies to date, the side effects of norfloxacin have been minimal, but include nausea, vomiting, anorexia, dizziness, headache, drowsiness, depression, and a bitter taste in the mouth. In studies with more than 4000 patients, the incidence of side effects ranged from 3.9 to 4.7 percent, with most appearing by the second day of therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516615     DOI: 10.1177/106002808602000402

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  5 in total

1.  Antibacterial activity of norfloxacin against bacterial isolates from the urinary tract.

Authors:  S M Qadri; S Johnson
Journal:  J Natl Med Assoc       Date:  1989-04       Impact factor: 1.798

Review 2.  Irritable bowel syndrome: a microbiome-gut-brain axis disorder?

Authors:  Paul J Kennedy; John F Cryan; Timothy G Dinan; Gerard Clarke
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

3.  Some biological properties of new quinoline-4-carboxylic acid and quinoline-4-carboxamide derivatives.

Authors:  J Strigácová; D Hudecová; L Varecka; A Lásiková; D Végh
Journal:  Folia Microbiol (Praha)       Date:  2000       Impact factor: 2.099

4.  Inappropriate breast secretions of possible bacterial etiology in the parous nonpuerperal female.

Authors:  J J Freeman; R H Altieri; A H Freeman; T Kuo; F Sardinha; C C Buckingham; J J Sklar; K Dyroff; A Floyd
Journal:  J Natl Med Assoc       Date:  1994-03       Impact factor: 1.798

5.  Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.

Authors:  S Segev; M Rehavi; E Rubinstein
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.